Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and Pembrolizumab in Advanced HCC
NCT04442581Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Apr 2021
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib and pembrolizumab in hepatocellular carcinoma (HCC), sponsored by University of Washington. Primary endpoint: Objective Response Rate. Started Apr 2021; status: terminated.
02
Drugs
cabozantinibpembrolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04442581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04442581.